Developer docs
API playgroundTry for free, no card

Search company profiles

Lifeline Biotechnologies

Full company profile

uuid003hafz

Namestring
Lifeline Biotechnologies
Websiteurl
lbti.com
Company typeenum
Private
Founded yearint
1981
Descriptiontext

Lifeline Biotechnologies, Inc. is a publicly traded medical technology company (otcpink:LLBO) headquartered in Reno, Nevada, founded in 1981. Per its firmographic profile, the company develops diagnostic equipment intended for the prevention, early diagnosis, and rapid assessment of medical conditions — though specific products, indications, technical architecture, and regulatory clearances are not disclosed in the available materials. The firm operates with a lean leadership team of Jim Holmes (President & CEO) and Fred V. Schiemann (CFO), and employs between 101 and 250 people.

The company's commercial mechanics are not detailed in the input: no revenue, pricing, distribution channel, or customer information has been disclosed, and the only documented funding event is a $200,000 round in October 2009 from unnamed investors. In May 2025, Lifeline acquired GlobalOdds for an undisclosed sum, which represents the most significant recent strategic event and suggests a directional pivot or diversification into sports betting/odds technology — a notable departure from the legacy diagnostic equipment thesis and one that warrants further diligence. The input also contains material data quality concerns: the company's own website (lbti.com) appears to display content for an unrelated Chinese boron-lithium chemical manufacturer, and the financial figures supplied show implausible multi-trillion-dollar values that are inconsistent with a small-cap OTC medtech firm and should be treated as data artifacts rather than company facts.

Short descriptiontext

Lifeline Biotechnologies is a publicly traded Reno, Nevada–based medical technology company (founded 1981, otcpink:LLBO) developing diagnostic equipment for prevention and early diagnosis, which in May 2025 acquired GlobalOdds in a notable diversification move.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersReno, United States
HQ citystring
Reno
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical diagnostic equipment, early disease detection, preventive diagnostic devices, clinical diagnostic technology, biotechnology diagnostic systems
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Diagnostic Equipment
No data
Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Lifeline Biotechnologies, Inc. is a medical technology company that develops diagnostic equipment intended for the prevention, early diagnosis, and rapid clinical assessment of disease. The company's offerings are positioned as devices used by healthcare providers in diagnostic workflows.

Differentiator
Functional benefit
Problem solved
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers8 records
1Bio-Rad Laboratories
TypeBroad incumbent
Description

Manufactures clinical diagnostics instruments and life science research products. Comparable as a developer of diagnostic equipment serving clinical and research customers.

2Exact Sciences
TypeEmerging player
Description

Diagnostics company focused on early cancer detection using proprietary platforms. Comparable in mission (early diagnosis, prevention-oriented testing) even if channel mix differs.

3Hologic
TypeBroad incumbent
Description

Major diagnostic and medical device company with broad portfolios in women's health, diagnostics, and surgical solutions. Comparable as a diagnostic equipment developer and the kind of large incumbent that could license or acquire Lifeline's IP.

4Qiagen
TypeBroad incumbent
Description

Provider of sample-prep and molecular diagnostic technologies. Comparable as a diagnostic equipment / consumables company with research and clinical customers.

5QuidelOrtho
TypeBroad incumbent
Description

Diagnostics-focused public company producing immunoassay and molecular diagnostic equipment. Operates in the same diagnostic-device end market Lifeline claims to serve.

6Cepheid (Danaher)
TypeBroad incumbent
Description

Developer of molecular diagnostic systems (GeneXpert). Directly comparable category — diagnostic instruments for early and rapid disease detection.

7Abbott Diagnostics
TypeBroad incumbent
Description

Division of Abbott producing a wide range of in-vitro diagnostic instruments and rapid tests. Represents a comparable large-scale diagnostic equipment business model.

8GenMark Diagnostics (Roche)
TypeDirect peer
Description

Developed molecular diagnostic panels and instruments (now part of Roche). Closely aligned as a smaller diagnostic-equipment developer that was eventually acquired.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lifeline Biotechnologies

Medical Diagnostic Equipmentlbti.com

Lifeline Biotechnologies is a publicly traded Reno, Nevada–based medical technology company (founded 1981, otcpink:LLBO) developing diagnostic equipment for prevention and early diagnosis, which in May 2025 acquired GlobalOdds in a notable diversification move.

What Lifeline Biotechnologies does

Lifeline Biotechnologies, Inc. is a publicly traded medical technology company (otcpink:LLBO) headquartered in Reno, Nevada, founded in 1981. Per its firmographic profile, the company develops diagnostic equipment intended for the prevention, early diagnosis, and rapid assessment of medical conditions — though specific products, indications, technical architecture, and regulatory clearances are not disclosed in the available materials. The firm operates with a lean leadership team of Jim Holmes (President & CEO) and Fred V. Schiemann (CFO), and employs between 101 and 250 people.

The company's commercial mechanics are not detailed in the input: no revenue, pricing, distribution channel, or customer information has been disclosed, and the only documented funding event is a $200,000 round in October 2009 from unnamed investors. In May 2025, Lifeline acquired GlobalOdds for an undisclosed sum, which represents the most significant recent strategic event and suggests a directional pivot or diversification into sports betting/odds technology — a notable departure from the legacy diagnostic equipment thesis and one that warrants further diligence. The input also contains material data quality concerns: the company's own website (lbti.com) appears to display content for an unrelated Chinese boron-lithium chemical manufacturer, and the financial figures supplied show implausible multi-trillion-dollar values that are inconsistent with a small-cap OTC medtech firm and should be treated as data artifacts rather than company facts.

Lifeline Biotechnologies firmographics

Firmographics
Name
Lifeline Biotechnologies
Website
https://lbti.com
Company type
Private
Founded year
1981
Headcount range
101–250 employees
Short description
Lifeline Biotechnologies is a publicly traded Reno, Nevada–based medical technology company (founded 1981, otcpink:LLBO) developing diagnostic equipment for prevention and early diagnosis, which in May 2025 acquired GlobalOdds in a notable diversification move.
Ownership category
akta.pro rank

Where Lifeline Biotechnologies is headquartered

Location

Headquarters

HQ city
Reno
HQ country
United States
HQ region
North America

Markets served

Lifeline Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Lifeline Biotechnologies product offering

Product offering

Core offering

Lifeline Biotechnologies, Inc. is a medical technology company that develops diagnostic equipment intended for the prevention, early diagnosis, and rapid clinical assessment of disease. The company's offerings are positioned as devices used by healthcare providers in diagnostic workflows.

Differentiator

Problem solved

Functional benefit

Companies that use Lifeline Biotechnologies

Customer profile

Ideal customer profiles1 record

Lifeline Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Lifeline Biotechnologies partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Lifeline Biotechnologies competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Manufactures clinical diagnostics instruments and life science research products. Comparable as a developer of diagnostic equipment serving clinical and research customers.
  • Hologic: Major diagnostic and medical device company with broad portfolios in women's health, diagnostics, and surgical solutions. Comparable as a diagnostic equipment developer and the kind of large incumbent that could license or acquire Lifeline's IP.
  • Qiagen: Provider of sample-prep and molecular diagnostic technologies. Comparable as a diagnostic equipment / consumables company with research and clinical customers.
  • QuidelOrtho: Diagnostics-focused public company producing immunoassay and molecular diagnostic equipment. Operates in the same diagnostic-device end market Lifeline claims to serve.
  • Cepheid (Danaher): Developer of molecular diagnostic systems (GeneXpert). Directly comparable category — diagnostic instruments for early and rapid disease detection.
  • Abbott Diagnostics: Division of Abbott producing a wide range of in-vitro diagnostic instruments and rapid tests. Represents a comparable large-scale diagnostic equipment business model.

Emerging players

  • Exact Sciences: Diagnostics company focused on early cancer detection using proprietary platforms. Comparable in mission (early diagnosis, prevention-oriented testing) even if channel mix differs.

Direct peers

  • GenMark Diagnostics (Roche): Developed molecular diagnostic panels and instruments (now part of Roche). Closely aligned as a smaller diagnostic-equipment developer that was eventually acquired.

Market position

Strengths2 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights3 records

Customer concentration

Lifeline Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lifeline Biotechnologies leadership team

Management profile

Number of profiles

Profiles2 records

Lifeline Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lifeline Biotechnologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lifeline Biotechnologies

What does Lifeline Biotechnologies do?

Lifeline Biotechnologies, Inc. is a medical technology company that develops diagnostic equipment intended for the prevention, early diagnosis, and rapid clinical assessment of disease. The company's offerings are positioned as devices used by healthcare providers in diagnostic workflows.

When was Lifeline Biotechnologies founded?

Lifeline Biotechnologies was founded in 1981. It employs 101 to 250 people.

Where is Lifeline Biotechnologies based?

Lifeline Biotechnologies is headquartered in Reno, United States, in the North America region.

Who are Lifeline Biotechnologies's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Hologic, Qiagen, QuidelOrtho, Cepheid (Danaher) and Abbott Diagnostics. Exact Sciences is listed as an emerging player. GenMark Diagnostics (Roche) is listed as a direct peer.

Does Lifeline Biotechnologies have an API?

No public API is recorded for Lifeline Biotechnologies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireLifeline Biotechnologies UpdatesLifeline Biotechnologies transferred its breast cancer detection technology to Cyrcadia, Inc. in exchange for 4,670,000 Cyrcadia shares, $110,000 cash, and a $220,000 note, increasing Lifeline's stake to over 45%. Cyrcadia will license the technology to Cyrcadia Asia Limited for Asian markets, with a transaction valued at approximately $5 million.GlobeNewswireLifeline Biotechnologies Announces a Cyrcadia Milestone and 2016 ExpectationsCyrcadia Health, an affiliate of Lifeline Biotechnologies, extended its early breast cancer detection trial to The Ohio State University, adding Columbus, Ohio, to the study. The trial, which began in 2015 at El Camino Hospital, will enroll 173 patients. Cyrcadia expects to file a 510(k) clearance notification with the FDA parallel with enrollment completion.GlobeNewswireLifeline Biotechnologies (LLBO) Q1 2015 UpdateLifeline Biotechnologies updated its Q1 2015 activities, noting Cyrcadia's clinical trials at El Camino Hospital and Ohio State University are underway. The trials, approved by IRBs, are expected to complete in four to six months, with CE marking and FDA 510(k) submission following. International sales are projected for Q4 2015 and US sales for Q1-Q2 2016.GlobeNewswireEarly Stock Market Alerts for Monday, February 9, 2004: EVSC, GMDP, LBTT, VNTBTheSUBWAY.com named Endovasc Inc. to its Stock Pick List, citing recent positive news and expecting a near-term move. Other highlighted stocks include Global Medical Products Holdings, Lifeline BioTechnologies, and V-Net Beverage, with ratings based on fundamental and technical analysis. The opinion is a forward-looking statement with risks and uncertainties.GlobeNewswireMorning Stock Pick List for Tuesday, January 27, 2004: WLFI, PRIM, TFSM, LBTTTheSUBWAY.com's stock pick list for Tuesday, January 27, 2004, names Weight Loss Forever International, Prime Holdings, 24/7 Real Media, and Lifeline BioTechnologies. The list includes market performance ratings and notes Capital Research Group's share sales, including 75,000 shares sold to date.GlobeNewswireTheSUBWAY.com Announces Its Morning Stock Focus List for Wednesday, December 10, 2003: MSSI, DYTK, CTKH, LBTTTheSUBWAY.com added MSSI-TeleScience International to its Stock Focus List, citing a near-term move. Other highlighted stocks include DynTek, Cetek Technologies, and Lifeline BioTechnologies, with ratings based on fundamental and technical analysis. The company also disclosed that CRG has sold approximately 360,000 shares of MSSI.